"HIV Long Terminal Repeat" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Regulatory sequences important for viral replication that are located on each end of the HIV genome. The LTR includes the HIV ENHANCER, promoter, and other sequences. Specific regions in the LTR include the negative regulatory element (NRE), NF-kappa B binding sites , Sp1 binding sites, TATA BOX, and trans-acting responsive element (TAR). The binding of both cellular and viral proteins to these regions regulates HIV transcription.
| Descriptor ID |
D016325
|
| MeSH Number(s) |
G02.111.570.080.708.850.400 G05.360.080.708.850.400
|
| Concept/Terms |
HIV Long Terminal Repeat- HIV Long Terminal Repeat
- LTR, Human Immunodeficiency Virus
- Human Immunodeficiency Virus LTR
- Long Terminal Repeat, HIV
- Human Immunodeficiency Virus Long Terminal Repeat
Trans-Acting Responsive Region, HIV- Trans-Acting Responsive Region, HIV
- Trans Acting Responsive Region, HIV
- HIV Trans-Acting Responsive Region
- HIV Trans Acting Responsive Region
- Trans-Activation Responsive Element, HIV
- Trans Activation Responsive Element, HIV
- Trans-Activation Responsive Region, HIV
- Trans Activation Responsive Region, HIV
- TAR Element, HIV
- HIV TAR Element
- HIV TAR Elements
- TAR Elements, HIV
Sp1-Binding Site, HIV- Sp1-Binding Site, HIV
- Sp1 Binding Site, HIV
- HIV Sp1-Binding Site
- HIV Sp1 Binding Site
- HIV Sp1-Binding Sites
- Sp1-Binding Sites, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Long Terminal Repeat".
Below are MeSH descriptors whose meaning is more specific than "HIV Long Terminal Repeat".
This graph shows the total number of publications written about "HIV Long Terminal Repeat" by people in this website by year, and whether "HIV Long Terminal Repeat" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Long Terminal Repeat" by people in Profiles.
-
Lee SK, Potempa M, Kolli M, ?zen A, Schiffer CA, Swanstrom R. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J Biol Chem. 2012 Apr 13; 287(16):13279-90.
-
De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology. 2011 Dec 06; 8:98.
-
Klatt A, Zhang Z, Kalantari P, Hankey PA, Gilmour DS, Henderson AJ. The receptor tyrosine kinase RON represses HIV-1 transcription by targeting RNA polymerase II processivity. J Immunol. 2008 Feb 01; 180(3):1670-7.
-
Sharma A, Awasthi S, Harrod CK, Matlock EF, Khan S, Xu L, Chan S, Yang H, Thammavaram CK, Rasor RA, Burns DK, Skiest DJ, Van Lint C, Girard AM, McGee M, Monnat RJ, Harrod R. The Werner syndrome helicase is a cofactor for HIV-1 long terminal repeat transactivation and retroviral replication. J Biol Chem. 2007 Apr 20; 282(16):12048-57.
-
Richter SN, B?langer F, Zheng P, Rana TM. Dynamics of nascent mRNA folding and RNA-protein interactions: an alternative TAR RNA structure is involved in the control of HIV-1 mRNA transcription. Nucleic Acids Res. 2006; 34(15):4278-92.
-
Cao H, Tamilarasu N, Rana TM. Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer. Bioconjug Chem. 2006 Mar-Apr; 17(2):352-8.
-
Lee CW, Cao H, Ichiyama K, Rana TM. Design and synthesis of a novel peptidomimetic inhibitor of HIV-1 Tat-TAR interactions: squaryldiamide as a new potential bioisostere of unsubstituted guanidine. Bioorg Med Chem Lett. 2005 Oct 01; 15(19):4243-6.
-
Brown KM, Chu CY, Rana TM. Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol. 2005 May; 12(5):469-70.
-
Hiebenthal-Millow K, Greenough TC, Bretttler DB, Schindler M, Wildum S, Sullivan JL, Kirchhoff F. Alterations in HIV-1 LTR promoter activity during AIDS progression. Virology. 2003 Dec 05; 317(1):109-18.
-
Gelman MA, Richter S, Cao H, Umezawa N, Gellman SH, Rana TM. Selective binding of TAR RNA by a Tat-derived beta-peptide. Org Lett. 2003 Oct 02; 5(20):3563-5.